Jeffrey Swigris
Concepts (324)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Idiopathic Pulmonary Fibrosis | 46 | 2019 | 500 | 8.920 |
Why?
| Lung Diseases, Interstitial | 39 | 2019 | 495 | 6.340 |
Why?
| Pulmonary Fibrosis | 19 | 2019 | 321 | 5.170 |
Why?
| Quality of Life | 30 | 2019 | 2343 | 3.840 |
Why?
| Oxygen Inhalation Therapy | 10 | 2019 | 127 | 3.370 |
Why?
| Dyspnea | 18 | 2019 | 212 | 3.330 |
Why?
| Surveys and Questionnaires | 29 | 2019 | 4595 | 2.550 |
Why?
| Connective Tissue Diseases | 13 | 2019 | 71 | 2.510 |
Why?
| Vital Capacity | 25 | 2019 | 254 | 2.050 |
Why?
| Lymphangioleiomyomatosis | 4 | 2015 | 27 | 1.460 |
Why?
| Pyridones | 8 | 2018 | 122 | 1.350 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 8 | 2018 | 296 | 1.330 |
Why?
| Walking | 7 | 2013 | 422 | 1.290 |
Why?
| Lung | 17 | 2018 | 3521 | 1.160 |
Why?
| Aged | 56 | 2019 | 18969 | 1.140 |
Why?
| Arthritis, Rheumatoid | 7 | 2018 | 1002 | 1.120 |
Why?
| Patients | 3 | 2018 | 163 | 1.070 |
Why?
| Respiratory Function Tests | 16 | 2019 | 522 | 1.070 |
Why?
| Middle Aged | 65 | 2019 | 26605 | 1.060 |
Why?
| Research Design | 5 | 2016 | 919 | 1.040 |
Why?
| Health Care Costs | 3 | 2018 | 381 | 1.010 |
Why?
| Exercise Test | 8 | 2018 | 547 | 0.980 |
Why?
| Alveolitis, Extrinsic Allergic | 4 | 2019 | 83 | 0.980 |
Why?
| Health Status Indicators | 4 | 2014 | 155 | 0.980 |
Why?
| Humans | 117 | 2019 | 114045 | 0.950 |
Why?
| Sarcoidosis | 4 | 2016 | 133 | 0.870 |
Why?
| Male | 74 | 2019 | 55396 | 0.860 |
Why?
| Female | 77 | 2019 | 59324 | 0.840 |
Why?
| Patient Outcome Assessment | 2 | 2014 | 122 | 0.830 |
Why?
| Mycophenolic Acid | 4 | 2016 | 76 | 0.820 |
Why?
| Patient Reported Outcome Measures | 4 | 2018 | 251 | 0.800 |
Why?
| Severity of Illness Index | 16 | 2018 | 2537 | 0.780 |
Why?
| Internet | 2 | 2016 | 591 | 0.770 |
Why?
| Exercise Tolerance | 3 | 2018 | 212 | 0.760 |
Why?
| Oxygen | 4 | 2018 | 851 | 0.730 |
Why?
| Disease Progression | 14 | 2019 | 2371 | 0.730 |
Why?
| Forced Expiratory Volume | 10 | 2017 | 471 | 0.700 |
Why?
| Undifferentiated Connective Tissue Diseases | 1 | 2019 | 1 | 0.660 |
Why?
| Qualitative Research | 4 | 2017 | 919 | 0.620 |
Why?
| Indoles | 2 | 2018 | 300 | 0.600 |
Why?
| Cough | 4 | 2019 | 107 | 0.580 |
Why?
| Emphysema | 1 | 2018 | 106 | 0.580 |
Why?
| Lung Diseases | 3 | 2015 | 690 | 0.550 |
Why?
| Chronic Disease | 4 | 2018 | 1577 | 0.550 |
Why?
| Pulmonary Medicine | 2 | 2015 | 69 | 0.550 |
Why?
| Lung Transplantation | 1 | 2019 | 244 | 0.550 |
Why?
| Psychometrics | 8 | 2017 | 608 | 0.540 |
Why?
| Immunosuppressive Agents | 4 | 2016 | 641 | 0.540 |
Why?
| Heart Rate | 2 | 2011 | 710 | 0.530 |
Why?
| Ambulatory Care | 2 | 2018 | 479 | 0.510 |
Why?
| Pulmonary Emphysema | 1 | 2018 | 267 | 0.510 |
Why?
| Idiopathic Interstitial Pneumonias | 6 | 2017 | 46 | 0.500 |
Why?
| Information Seeking Behavior | 1 | 2016 | 35 | 0.500 |
Why?
| Narration | 1 | 2016 | 44 | 0.500 |
Why?
| Longitudinal Studies | 8 | 2019 | 2384 | 0.470 |
Why?
| Biomedical Research | 2 | 2018 | 582 | 0.460 |
Why?
| Kaplan-Meier Estimate | 8 | 2018 | 813 | 0.460 |
Why?
| Fatigue | 6 | 2019 | 294 | 0.460 |
Why?
| Caregivers | 3 | 2017 | 713 | 0.460 |
Why?
| Autoimmunity | 2 | 2019 | 812 | 0.450 |
Why?
| Autoimmune Diseases | 3 | 2016 | 381 | 0.450 |
Why?
| Reproducibility of Results | 11 | 2019 | 2764 | 0.450 |
Why?
| Patient-Centered Care | 1 | 2018 | 470 | 0.430 |
Why?
| Social Support | 2 | 2019 | 528 | 0.430 |
Why?
| Social Media | 1 | 2016 | 131 | 0.430 |
Why?
| Antitussive Agents | 1 | 2013 | 8 | 0.420 |
Why?
| Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 907 | 0.420 |
Why?
| Tomography, X-Ray Computed | 12 | 2018 | 2272 | 0.420 |
Why?
| Motivation | 1 | 2017 | 488 | 0.420 |
Why?
| Thalidomide | 1 | 2013 | 28 | 0.420 |
Why?
| Lung Neoplasms | 3 | 2014 | 2159 | 0.420 |
Why?
| Prognosis | 12 | 2018 | 3315 | 0.410 |
Why?
| Bronchiolitis Obliterans | 1 | 2013 | 66 | 0.410 |
Why?
| United States | 21 | 2019 | 12137 | 0.410 |
Why?
| Follow-Up Studies | 9 | 2018 | 4392 | 0.400 |
Why?
| Aged, 80 and over | 16 | 2017 | 6306 | 0.400 |
Why?
| Patient Participation | 1 | 2015 | 348 | 0.400 |
Why?
| Survival Rate | 6 | 2018 | 1638 | 0.400 |
Why?
| Bronchial Diseases | 1 | 2012 | 35 | 0.390 |
Why?
| Treatment Outcome | 16 | 2018 | 9049 | 0.380 |
Why?
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 1168 | 0.380 |
Why?
| Hospitalization | 3 | 2017 | 1762 | 0.370 |
Why?
| Quality Indicators, Health Care | 1 | 2014 | 285 | 0.370 |
Why?
| Adult | 31 | 2019 | 30375 | 0.360 |
Why?
| Pulmonary Diffusing Capacity | 6 | 2017 | 60 | 0.360 |
Why?
| Health Status | 5 | 2019 | 716 | 0.360 |
Why?
| Retrospective Studies | 21 | 2019 | 12521 | 0.360 |
Why?
| Multivariate Analysis | 5 | 2017 | 1422 | 0.350 |
Why?
| Peptides, Cyclic | 1 | 2012 | 252 | 0.350 |
Why?
| Motor Activity | 1 | 2014 | 635 | 0.340 |
Why?
| Endothelins | 1 | 2010 | 61 | 0.330 |
Why?
| Cause of Death | 6 | 2019 | 362 | 0.330 |
Why?
| Scleroderma, Systemic | 3 | 2017 | 90 | 0.330 |
Why?
| Gastroesophageal Reflux | 1 | 2012 | 229 | 0.330 |
Why?
| Activities of Daily Living | 3 | 2018 | 348 | 0.320 |
Why?
| Pulmonary Embolism | 1 | 2011 | 180 | 0.320 |
Why?
| Autoantibodies | 4 | 2015 | 1347 | 0.320 |
Why?
| Sleep Apnea, Obstructive | 1 | 2012 | 195 | 0.320 |
Why?
| TRPP Cation Channels | 1 | 2009 | 63 | 0.310 |
Why?
| Amino Acyl-tRNA Synthetases | 3 | 2016 | 28 | 0.300 |
Why?
| Endothelin-1 | 1 | 2010 | 168 | 0.300 |
Why?
| Polycystic Kidney Diseases | 1 | 2009 | 55 | 0.300 |
Why?
| Randomized Controlled Trials as Topic | 5 | 2017 | 1204 | 0.290 |
Why?
| Proportional Hazards Models | 3 | 2017 | 1078 | 0.280 |
Why?
| Prevalence | 5 | 2018 | 2247 | 0.280 |
Why?
| Hypertension, Pulmonary | 3 | 2017 | 1736 | 0.270 |
Why?
| Mortality | 4 | 2019 | 283 | 0.270 |
Why?
| Tumor Suppressor Proteins | 1 | 2009 | 283 | 0.270 |
Why?
| Biopsy | 7 | 2016 | 1024 | 0.270 |
Why?
| Sex Distribution | 3 | 2012 | 336 | 0.270 |
Why?
| Quality Improvement | 1 | 2014 | 944 | 0.270 |
Why?
| Cost of Illness | 3 | 2018 | 254 | 0.260 |
Why?
| Double-Blind Method | 6 | 2017 | 1656 | 0.260 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2008 | 220 | 0.250 |
Why?
| Thrombosis | 1 | 2008 | 295 | 0.230 |
Why?
| Databases, Factual | 3 | 2019 | 1125 | 0.230 |
Why?
| Prospective Studies | 8 | 2019 | 6195 | 0.230 |
Why?
| Time Factors | 7 | 2019 | 6077 | 0.230 |
Why?
| Vascular Endothelial Growth Factor D | 2 | 2013 | 12 | 0.220 |
Why?
| Oxygen Consumption | 2 | 2017 | 587 | 0.220 |
Why?
| Myositis | 2 | 2016 | 44 | 0.210 |
Why?
| Diagnosis, Differential | 6 | 2016 | 1331 | 0.210 |
Why?
| Palliative Care | 2 | 2019 | 641 | 0.200 |
Why?
| Incidence | 3 | 2018 | 2314 | 0.190 |
Why?
| Patient Satisfaction | 2 | 2016 | 571 | 0.190 |
Why?
| Focus Groups | 3 | 2016 | 378 | 0.180 |
Why?
| Sex Factors | 5 | 2016 | 1706 | 0.180 |
Why?
| Registries | 3 | 2019 | 1764 | 0.180 |
Why?
| Age Distribution | 2 | 2012 | 341 | 0.180 |
Why?
| Cohort Studies | 5 | 2019 | 4883 | 0.180 |
Why?
| Logistic Models | 4 | 2019 | 1829 | 0.170 |
Why?
| Analysis of Variance | 3 | 2015 | 1218 | 0.170 |
Why?
| Survival Analysis | 3 | 2017 | 1206 | 0.170 |
Why?
| Linear Models | 3 | 2019 | 768 | 0.170 |
Why?
| Walk Test | 2 | 2017 | 52 | 0.170 |
Why?
| Antibodies, Antinuclear | 4 | 2016 | 58 | 0.170 |
Why?
| Exercise | 3 | 2019 | 1642 | 0.170 |
Why?
| Sensitivity and Specificity | 3 | 2015 | 1690 | 0.170 |
Why?
| Risk Factors | 7 | 2017 | 8614 | 0.160 |
Why?
| Chi-Square Distribution | 2 | 2011 | 492 | 0.160 |
Why?
| Anxiety | 3 | 2019 | 843 | 0.160 |
Why?
| Pulmonologists | 1 | 2018 | 13 | 0.160 |
Why?
| Insurance Claim Review | 1 | 2018 | 68 | 0.150 |
Why?
| Accelerometry | 2 | 2019 | 73 | 0.150 |
Why?
| Cross-Sectional Studies | 4 | 2019 | 4402 | 0.150 |
Why?
| Cellular Senescence | 1 | 2019 | 151 | 0.150 |
Why?
| Attitude to Health | 2 | 2014 | 398 | 0.140 |
Why?
| Weight-Bearing | 1 | 2018 | 164 | 0.140 |
Why?
| Germany | 1 | 2017 | 84 | 0.140 |
Why?
| Sulfonamides | 2 | 2010 | 444 | 0.140 |
Why?
| Antihypertensive Agents | 2 | 2010 | 428 | 0.140 |
Why?
| Medicare | 2 | 2018 | 661 | 0.140 |
Why?
| Perception | 1 | 2019 | 309 | 0.130 |
Why?
| Host-Pathogen Interactions | 1 | 2019 | 295 | 0.130 |
Why?
| Common Variable Immunodeficiency | 1 | 2016 | 25 | 0.130 |
Why?
| Tidal Volume | 1 | 2016 | 75 | 0.130 |
Why?
| Muscle Strength | 2 | 2015 | 271 | 0.130 |
Why?
| Granuloma | 1 | 2016 | 82 | 0.130 |
Why?
| Cyclophosphamide | 1 | 2016 | 214 | 0.130 |
Why?
| Interviews as Topic | 2 | 2016 | 575 | 0.130 |
Why?
| Home Care Services | 1 | 2018 | 219 | 0.130 |
Why?
| Patient Education as Topic | 2 | 2019 | 666 | 0.130 |
Why?
| Health Policy | 1 | 2018 | 330 | 0.130 |
Why?
| Physical Conditioning, Human | 1 | 2015 | 27 | 0.120 |
Why?
| Case-Control Studies | 4 | 2019 | 3003 | 0.120 |
Why?
| Rituximab | 1 | 2016 | 148 | 0.120 |
Why?
| Recovery of Function | 1 | 2018 | 573 | 0.120 |
Why?
| Sarcoidosis, Pulmonary | 1 | 2015 | 57 | 0.120 |
Why?
| Neuroendocrine Cells | 1 | 2015 | 30 | 0.120 |
Why?
| Enzyme Inhibitors | 2 | 2016 | 743 | 0.120 |
Why?
| Geographic Information Systems | 1 | 2014 | 37 | 0.120 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2013 | 27 | 0.110 |
Why?
| Phenotype | 2 | 2018 | 2784 | 0.110 |
Why?
| Information Dissemination | 1 | 2016 | 185 | 0.110 |
Why?
| Sildenafil Citrate | 1 | 2013 | 57 | 0.110 |
Why?
| Antifibrinolytic Agents | 1 | 2014 | 43 | 0.110 |
Why?
| Self Report | 2 | 2019 | 695 | 0.110 |
Why?
| Endpoint Determination | 1 | 2013 | 68 | 0.110 |
Why?
| Sulfones | 1 | 2013 | 97 | 0.110 |
Why?
| Occupational Exposure | 1 | 2016 | 255 | 0.110 |
Why?
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2013 | 38 | 0.110 |
Why?
| Adaptation, Psychological | 1 | 2017 | 545 | 0.100 |
Why?
| Antibiotics, Antineoplastic | 1 | 2013 | 110 | 0.100 |
Why?
| Purines | 1 | 2013 | 158 | 0.100 |
Why?
| Patient Dropouts | 1 | 2013 | 66 | 0.100 |
Why?
| Young Adult | 5 | 2017 | 10444 | 0.100 |
Why?
| Sirolimus | 1 | 2013 | 181 | 0.100 |
Why?
| Histocompatibility Antigens Class II | 1 | 2013 | 350 | 0.100 |
Why?
| Pulmonary Gas Exchange | 1 | 2012 | 117 | 0.100 |
Why?
| Vasodilator Agents | 1 | 2013 | 302 | 0.100 |
Why?
| Delivery of Health Care | 1 | 2018 | 828 | 0.100 |
Why?
| Health Care Surveys | 1 | 2014 | 541 | 0.100 |
Why?
| Minnesota | 1 | 2012 | 132 | 0.100 |
Why?
| Exercise Therapy | 1 | 2015 | 351 | 0.100 |
Why?
| Fear | 1 | 2014 | 292 | 0.090 |
Why?
| Piperazines | 1 | 2013 | 310 | 0.090 |
Why?
| Dust | 1 | 2012 | 84 | 0.090 |
Why?
| Consensus | 1 | 2013 | 532 | 0.090 |
Why?
| United Kingdom | 1 | 2012 | 226 | 0.090 |
Why?
| Clinical Trials as Topic | 2 | 2006 | 926 | 0.090 |
Why?
| Hydrogen-Ion Concentration | 1 | 2012 | 507 | 0.090 |
Why?
| Pilot Projects | 2 | 2015 | 1360 | 0.090 |
Why?
| Health Surveys | 1 | 2012 | 441 | 0.090 |
Why?
| Anti-Infective Agents | 1 | 2013 | 219 | 0.090 |
Why?
| Epidemiologic Methods | 1 | 2010 | 72 | 0.090 |
Why?
| Societies, Medical | 4 | 2015 | 655 | 0.080 |
Why?
| Sickness Impact Profile | 2 | 2009 | 50 | 0.080 |
Why?
| Salivary Glands, Minor | 1 | 2009 | 8 | 0.080 |
Why?
| Smoking | 2 | 2017 | 1382 | 0.080 |
Why?
| Sjogren's Syndrome | 1 | 2009 | 41 | 0.080 |
Why?
| International Cooperation | 3 | 2015 | 169 | 0.080 |
Why?
| Hyperplasia | 2 | 2015 | 163 | 0.080 |
Why?
| Oximetry | 1 | 2009 | 79 | 0.080 |
Why?
| Risk | 1 | 2011 | 810 | 0.080 |
Why?
| Europe | 3 | 2015 | 332 | 0.080 |
Why?
| Environmental Exposure | 1 | 2012 | 372 | 0.080 |
Why?
| Scleroderma, Limited | 1 | 2008 | 5 | 0.080 |
Why?
| Depression | 2 | 2019 | 1133 | 0.070 |
Why?
| Poisson Distribution | 3 | 2016 | 71 | 0.070 |
Why?
| Wound Healing | 1 | 2010 | 254 | 0.070 |
Why?
| Sleep Wake Disorders | 1 | 2011 | 232 | 0.070 |
Why?
| Bronchoalveolar Lavage Fluid | 1 | 2010 | 580 | 0.070 |
Why?
| Comorbidity | 2 | 2017 | 1447 | 0.070 |
Why?
| Radiography | 2 | 2016 | 803 | 0.070 |
Why?
| Cardiac Catheterization | 1 | 2011 | 545 | 0.070 |
Why?
| Models, Statistical | 1 | 2011 | 595 | 0.070 |
Why?
| Predictive Value of Tests | 2 | 2009 | 1791 | 0.070 |
Why?
| Evidence-Based Medicine | 1 | 2011 | 662 | 0.070 |
Why?
| Pericardium | 1 | 2007 | 50 | 0.070 |
Why?
| Carbon Monoxide | 2 | 2017 | 64 | 0.070 |
Why?
| Physicians | 1 | 2014 | 765 | 0.070 |
Why?
| Clinical Trials, Phase III as Topic | 2 | 2016 | 82 | 0.070 |
Why?
| Seasons | 1 | 2008 | 440 | 0.060 |
Why?
| Medical Records | 1 | 2006 | 153 | 0.060 |
Why?
| Regression Analysis | 3 | 2016 | 945 | 0.060 |
Why?
| California | 1 | 2005 | 351 | 0.060 |
Why?
| Echocardiography | 1 | 2007 | 569 | 0.060 |
Why?
| Acute Disease | 1 | 2006 | 907 | 0.060 |
Why?
| Data Interpretation, Statistical | 2 | 2018 | 318 | 0.050 |
Why?
| Terminology as Topic | 1 | 2005 | 186 | 0.050 |
Why?
| Lymphoid Tissue | 1 | 2002 | 62 | 0.050 |
Why?
| Patient Selection | 1 | 2005 | 629 | 0.050 |
Why?
| Adolescent | 3 | 2017 | 17800 | 0.050 |
Why?
| Disease Models, Animal | 1 | 2010 | 3498 | 0.040 |
Why?
| Respiratory Therapy | 1 | 2019 | 19 | 0.040 |
Why?
| Pulmonary Surfactant-Associated Protein A | 1 | 2019 | 24 | 0.040 |
Why?
| Occupations | 1 | 2019 | 35 | 0.040 |
Why?
| GTPase-Activating Proteins | 1 | 2019 | 72 | 0.040 |
Why?
| Pulmonary Surfactant-Associated Protein C | 1 | 2019 | 42 | 0.040 |
Why?
| Exoribonucleases | 1 | 2019 | 40 | 0.040 |
Why?
| Blood Gas Analysis | 1 | 2019 | 70 | 0.040 |
Why?
| Minimal Clinically Important Difference | 1 | 2018 | 10 | 0.040 |
Why?
| ATP-Binding Cassette Transporters | 1 | 2019 | 122 | 0.040 |
Why?
| Asthma | 1 | 2011 | 2021 | 0.040 |
Why?
| Telomere-Binding Proteins | 1 | 2019 | 88 | 0.040 |
Why?
| Patient Advocacy | 1 | 2018 | 65 | 0.040 |
Why?
| Education | 1 | 2018 | 93 | 0.040 |
Why?
| Watchful Waiting | 1 | 2018 | 54 | 0.040 |
Why?
| DNA Helicases | 1 | 2019 | 133 | 0.040 |
Why?
| Administrative Claims, Healthcare | 1 | 2017 | 22 | 0.040 |
Why?
| Physical Endurance | 1 | 2019 | 232 | 0.040 |
Why?
| Forecasting | 1 | 2019 | 331 | 0.040 |
Why?
| Mucin-5B | 1 | 2019 | 184 | 0.040 |
Why?
| Needs Assessment | 1 | 2019 | 315 | 0.040 |
Why?
| Telomerase | 1 | 2019 | 204 | 0.040 |
Why?
| Spirometry | 1 | 2017 | 223 | 0.030 |
Why?
| Hypersplenism | 1 | 2016 | 7 | 0.030 |
Why?
| Leukopenia | 1 | 2016 | 27 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 2019 | 722 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 437 | 0.030 |
Why?
| Banking, Personal | 1 | 2016 | 3 | 0.030 |
Why?
| Social Participation | 1 | 2016 | 13 | 0.030 |
Why?
| Terminal Care | 1 | 2019 | 212 | 0.030 |
Why?
| Creatine Kinase | 1 | 2016 | 75 | 0.030 |
Why?
| Rheumatoid Factor | 1 | 2017 | 157 | 0.030 |
Why?
| Health Care Sector | 1 | 2016 | 24 | 0.030 |
Why?
| Death Certificates | 1 | 2016 | 30 | 0.030 |
Why?
| Health Services Needs and Demand | 1 | 2017 | 240 | 0.030 |
Why?
| Commerce | 1 | 2016 | 61 | 0.030 |
Why?
| Arthritis | 1 | 2016 | 109 | 0.030 |
Why?
| Metals | 1 | 2016 | 105 | 0.030 |
Why?
| International Classification of Diseases | 1 | 2016 | 116 | 0.030 |
Why?
| Promoter Regions, Genetic | 1 | 2019 | 1131 | 0.030 |
Why?
| Multiple Pulmonary Nodules | 1 | 2015 | 22 | 0.030 |
Why?
| Anthropometry | 1 | 2015 | 183 | 0.030 |
Why?
| Physical Examination | 1 | 2016 | 221 | 0.030 |
Why?
| Genetic Variation | 1 | 2019 | 868 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2016 | 618 | 0.030 |
Why?
| Alberta | 1 | 2013 | 10 | 0.030 |
Why?
| Teaching | 1 | 2016 | 209 | 0.030 |
Why?
| Bronchiolitis | 1 | 2015 | 81 | 0.030 |
Why?
| Mortality, Premature | 1 | 2013 | 11 | 0.030 |
Why?
| Counseling | 1 | 2016 | 342 | 0.030 |
Why?
| RNA | 1 | 2019 | 806 | 0.030 |
Why?
| Odds Ratio | 1 | 2016 | 951 | 0.030 |
Why?
| Genome-Wide Association Study | 1 | 2019 | 1176 | 0.030 |
Why?
| Adrenal Cortex Hormones | 1 | 2016 | 493 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2016 | 949 | 0.030 |
Why?
| Inflammation | 1 | 2002 | 2464 | 0.030 |
Why?
| Congresses as Topic | 1 | 2013 | 193 | 0.030 |
Why?
| Administration, Oral | 1 | 2014 | 725 | 0.020 |
Why?
| Age Factors | 2 | 2010 | 2885 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2016 | 1836 | 0.020 |
Why?
| Genetic Predisposition to Disease | 1 | 2019 | 2090 | 0.020 |
Why?
| Japan | 1 | 2011 | 85 | 0.020 |
Why?
| Antigens, Human Platelet | 1 | 2011 | 9 | 0.020 |
Why?
| Latin America | 1 | 2011 | 68 | 0.020 |
Why?
| Mental Health | 1 | 2016 | 559 | 0.020 |
Why?
| Alanine-tRNA Ligase | 1 | 2009 | 4 | 0.020 |
Why?
| Threonine-tRNA Ligase | 1 | 2009 | 4 | 0.020 |
Why?
| Psychiatric Status Rating Scales | 1 | 2011 | 481 | 0.020 |
Why?
| Animals | 1 | 2010 | 31565 | 0.020 |
Why?
| Syndrome | 1 | 2009 | 330 | 0.020 |
Why?
| DNA Topoisomerases, Type I | 1 | 2008 | 16 | 0.020 |
Why?
| Body Mass Index | 1 | 2015 | 1957 | 0.020 |
Why?
| Cell Proliferation | 1 | 2015 | 2173 | 0.020 |
Why?
| Lymphocytes | 1 | 2009 | 327 | 0.020 |
Why?
| Pulmonary Wedge Pressure | 1 | 2007 | 64 | 0.020 |
Why?
| Muscle, Skeletal | 1 | 2015 | 1468 | 0.020 |
Why?
| Risk Assessment | 1 | 2015 | 2958 | 0.020 |
Why?
| Child | 1 | 2002 | 18401 | 0.010 |
Why?
| Nuclear Proteins | 1 | 2008 | 591 | 0.010 |
Why?
| Biomarkers | 1 | 2013 | 3397 | 0.010 |
Why?
| Pneumonia | 1 | 2008 | 563 | 0.010 |
Why?
|
|
Swigris's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|